DK2101569T3 - Krystallinsk fast rasagilinbase - Google Patents

Krystallinsk fast rasagilinbase

Info

Publication number: DK2101569T3
Authority: DK; Denmark
Prior art keywords: crystalline solid; rasagiline base; solid rasagiline; base; aminoindan
Prior art date: 2006-12-14

Application number

DK07862906.0T

Other languages

English (en)

Inventor

Anton Frenkel

Tamas Koltai

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-14

Filing date

2007-12-13

Publication date

2012-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39536623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2101569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-13 Application filed by Teva Pharma filed Critical Teva Pharma

2012-01-30 Application granted granted Critical

2012-01-30 Publication of DK2101569T3 publication Critical patent/DK2101569T3/da

Links

RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
229960000245 rasagiline Drugs 0.000 title 1
239000007787 solid Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

DK07862906.0T 2006-12-14 2007-12-13 Krystallinsk fast rasagilinbase DK2101569T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87501106P	2006-12-14	2006-12-14
PCT/US2007/025583 WO2008076348A1 (en)	2006-12-14	2007-12-13	Crystalline solid rasagiline base

Publications (1)

Publication Number	Publication Date
DK2101569T3 true DK2101569T3 (da)	2012-01-30

Family

ID=39536623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07862906.0T DK2101569T3 (da)	2006-12-14	2007-12-13	Krystallinsk fast rasagilinbase

Country Status (24)

Country	Link
US (4)	US7750051B2 (da)
EP (1)	EP2101569B1 (da)
JP (1)	JP5623081B2 (da)
KR (1)	KR101459744B1 (da)
CN (1)	CN101557706B (da)
AT (1)	ATE528989T1 (da)
AU (1)	AU2007334428B2 (da)
CA (1)	CA2672414A1 (da)
CY (1)	CY1112511T1 (da)
DK (1)	DK2101569T3 (da)
EA (1)	EA016820B1 (da)
ES (1)	ES2375761T3 (da)
HR (1)	HRP20110980T1 (da)
IL (1)	IL198985A0 (da)
MX (1)	MX2009006251A (da)
NO (1)	NO20092611L (da)
NZ (1)	NZ577460A (da)
PL (1)	PL2101569T3 (da)
PT (1)	PT2101569E (da)
RS (1)	RS52183B (da)
SI (1)	SI2101569T1 (da)
UA (1)	UA97502C2 (da)
WO (1)	WO2008076348A1 (da)
ZA (1)	ZA200903903B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1778196A4 (en) *	2004-07-26	2008-12-17	Teva Pharma	PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) *	2004-11-24	2009-04-30	Shulamit Patashnik	Rasagiline Orally Disintegrating Compositions
HRP20130622T1 (en) *	2005-02-17	2013-08-31	Teva Pharmaceutical Industries Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2901244A1 (en)	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
JP2009521402A (ja) *	2005-11-17	2009-06-04	テバファーマシューティカルインダストリーズリミティド	プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
EP1991214B1 (en) *	2006-02-21	2015-08-05	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) *	2006-04-03	2009-07-01	Teva Pharma	USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
RS52183B (sr) *	2006-12-14	2012-10-31	Teva Pharmaceutical Industries, Ltd.	Kristalna čvrsta baza razagilina
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries, Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009089049A1 (en) *	2008-01-11	2009-07-16	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations, their preparation and use
AU2009254927B2 (en)	2008-06-02	2014-03-13	Generics [Uk] Limited	A process for the preparation of enantiomerically pure amines
US20100008983A1 (en) *	2008-06-10	2010-01-14	Muhammad Safadi	Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) *	2008-06-13	2015-07-28	Teva Pharma	"método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
BRPI0909997A2 (pt)	2008-06-19	2015-10-27	Teva Pharma	r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Process for purifying rasagiline base
CN101606923B (zh) *	2008-06-20	2013-01-09	重庆医药工业研究院有限责任公司	一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
ITMI20081406A1 (it) *	2008-07-29	2010-01-30	Dipharma Francis Srl	Forma cristallina di rasagilina e procedimento per la sua preparazione
EP2657221A1 (en)	2008-11-20	2013-10-30	Dr. Reddy's Laboratories Ltd.	Preparation of rasagiline and salts thereof
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
EP2218444A3 (en)	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
DK2451771T3 (da)	2009-07-09	2014-09-08	Ratiopharm Gmbh	Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2298277A1 (en) *	2009-09-09	2011-03-23	Labtec GmbH	Transdermal patch formulation
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2325159A1 (en)	2009-11-24	2011-05-25	LEK Pharmaceuticals d.d.	Novel salts of rasagiline
EP2515891A4 (en)	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
WO2011121607A2 (en)	2010-03-29	2011-10-06	Cadila Healthcare Limited	Rasagiline and its pharmaceutically acceptable salts
JP5820469B2 (ja)	2010-04-30	2015-11-24	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダンの経皮組成物
RU2587330C2 (ru)	2010-07-27	2016-06-20	Тева Фармасьютикал Индастриз Лтд.	Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en)	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Dispersion of rasagiline citrate
CN103476404B (zh)	2011-03-24	2017-09-29	帝国制药美国公司	包含活性剂层和活性剂转化层的透皮组合物
EP2705021A2 (en)	2011-05-04	2014-03-12	Cadila Healthcare Limited	Rasagiline and its pharmaceutically acceptable salts
HK1200314A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceuticals Usa, Inc.	R(+)-n-methyl-propargyl-aminoindan
HK1200315A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
EP2610239A1 (en)	2012-01-02	2013-07-03	Dr. Reddy's Laboratories Ltd.	Preparation Of Rasagiline Hemitartrate
EP2827848B1 (en)	2012-03-21	2016-04-27	Synthon BV	Stabilized pharmaceutical compositions comprising rasagiline salts
US9308182B2 (en)	2012-08-17	2016-04-12	Teva Pharmaceutical Industries, Ltd.	Parenteral formulations of rasagiline
AU2013338243B2 (en) *	2012-11-02	2016-09-29	Teikoku Seiyaku Co., Ltd.	Propynylaminoindan transdermal compositions

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4252951A (en) *	1979-10-09	1981-02-24	Eli Lilly And Company	Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US4529811A (en) *	1981-03-02	1985-07-16	G. D. Searle & Co.	Process for isolating organic compounds and lithium salt complexes useful in said process
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CN1031995C (zh) *	1991-01-02	1996-06-12	奥韦特有限公司	N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en)	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en)	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) *	1994-01-10	1999-03-02	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
PT807101E (pt)	1995-02-01	2001-12-28	Upjohn Co	2-aminoindanos comoligandos selectivos de dopamina d3
IL115357A (en)	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en)	1996-06-28	1997-09-02	Jame Fine Chemicals, Inc.	Process for preparing antihistamine tannates
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de)	1996-12-18	2008-08-28	Teva Pharmaceutical Industries Ltd.	Aminoindanderivate
US7150881B2 (en)	1997-06-26	2006-12-19	Mylan Technologies, Inc.	Adhesive mixture for transdermal delivery of highly plasticizing drugs
WO1999037293A2 (en)	1998-01-27	1999-07-29	Thomas Thomas N	Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
DE10041478A1 (de)	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
IL141690A (en) *	2001-02-27	2004-06-20	Isp Finetech Ltd	Process for preparation of rasagiline and its salts
US6543155B2 (en) *	2001-03-01	2003-04-08	National Agricultural Research Organization	Freeze-dried product and process and apparatus for producing it
DK1441708T3 (da) *	2001-11-05	2009-07-06	Krele Pharmaceuticals Llc	Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
US20050239054A1 (en) *	2002-04-26	2005-10-27	Arimilli Murty N	Method and compositions for identifying anti-HIV therapeutic compounds
US20040166159A1 (en) *	2002-05-29	2004-08-26	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
UA78854C2 (en) *	2002-09-06	2007-04-25	Kissei Pharmaceutical	Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
EP1567152B1 (en)	2002-11-15	2013-08-14	Teva Pharmaceutical Industries Limited	Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en)	2003-02-10	2004-08-12	Jame Fine Chemicals, Inc.	Opiod tannate compositions
EP2181995A3 (en)	2003-09-03	2010-06-16	Glaxo Group Limited	Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate
US7799273B2 (en) *	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
EP1778196A4 (en)	2004-07-26	2008-12-17	Teva Pharma	PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
EP1827409B1 (en)	2004-11-24	2011-08-24	Teva Pharmaceutical Industries, Ltd.	Rasagiline orally disintegrating compositions
US20090111892A1 (en) *	2004-11-24	2009-04-30	Shulamit Patashnik	Rasagiline Orally Disintegrating Compositions
CA2901244A1 (en)	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
JP2009521402A (ja)	2005-11-17	2009-06-04	テバファーマシューティカルインダストリーズリミティド	プロパルギル化アミノインダンの分離のための方法
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
EP1991214B1 (en) *	2006-02-21	2015-08-05	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh)	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP2007369A4 (en)	2006-04-03	2009-07-01	Teva Pharma	USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
US7573834B2 (en) *	2006-05-31	2009-08-11	Alcatel Lucent	Method and system for allocating a group bit rate among multiple bonded pairs in a communications network
EP1892233A1 (de) *	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
RS52183B (sr)	2006-12-14	2012-10-31	Teva Pharmaceutical Industries, Ltd.	Kristalna čvrsta baza razagilina
BRPI0718339A2 (pt)	2006-12-14	2014-02-18	Teva Pharma	Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en)	2007-09-05	2009-03-12	Teva Pharmaceutical Industries, Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en)	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
WO2009089049A1 (en)	2008-01-11	2009-07-16	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations, their preparation and use
WO2009122301A2 (en)	2008-03-31	2009-10-08	Actavis Group Ptc Ehf	Rasagiline mesylate particles and process for the preparation thereof
US20100008983A1 (en) *	2008-06-10	2010-01-14	Muhammad Safadi	Rasagiline soft gelatin capsules
CA2727021A1 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Process for purifying rasagiline base
BRPI0909997A2 (pt) *	2008-06-19	2015-10-27	Teva Pharma	r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
DE102008064061A1 (de) *	2008-12-19	2010-06-24	Ratiopharm Gmbh	Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
DK2451771T3 (da)	2009-07-09	2014-09-08	Ratiopharm Gmbh	Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
AU2010304755A1 (en) *	2009-10-09	2012-05-24	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) *	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
RU2587330C2 (ru) *	2010-07-27	2016-06-20	Тева Фармасьютикал Индастриз Лтд.	Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) *	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Dispersion of rasagiline citrate
MX2013004598A (es) *	2010-10-26	2013-07-17	Teva Pharma	Rasagilina enriquesida con deuterio.
HK1200314A1 (en) *	2011-10-10	2015-08-07	Teva Pharmaceuticals Usa, Inc.	R(+)-n-methyl-propargyl-aminoindan
JP2014534195A (ja) *	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトルアミド
HK1200315A1 (en) *	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan

2007
- 2007-12-13 RS RS20120016A patent/RS52183B/sr unknown
- 2007-12-13 PT PT07862906T patent/PT2101569E/pt unknown
- 2007-12-13 KR KR1020097014006A patent/KR101459744B1/ko not_active Expired - Fee Related
- 2007-12-13 CA CA002672414A patent/CA2672414A1/en not_active Abandoned
- 2007-12-13 SI SI200730807T patent/SI2101569T1/sl unknown
- 2007-12-13 MX MX2009006251A patent/MX2009006251A/es active IP Right Grant
- 2007-12-13 NZ NZ577460A patent/NZ577460A/en unknown
- 2007-12-13 ES ES07862906T patent/ES2375761T3/es active Active
- 2007-12-13 PL PL07862906T patent/PL2101569T3/pl unknown
- 2007-12-13 JP JP2009541390A patent/JP5623081B2/ja not_active Expired - Fee Related
- 2007-12-13 HR HR20110980T patent/HRP20110980T1/hr unknown
- 2007-12-13 EA EA200970581A patent/EA016820B1/ru not_active IP Right Cessation
- 2007-12-13 EP EP07862906A patent/EP2101569B1/en active Active
- 2007-12-13 WO PCT/US2007/025583 patent/WO2008076348A1/en not_active Ceased
- 2007-12-13 AU AU2007334428A patent/AU2007334428B2/en not_active Ceased
- 2007-12-13 ZA ZA200903903A patent/ZA200903903B/xx unknown
- 2007-12-13 AT AT07862906T patent/ATE528989T1/de active
- 2007-12-13 UA UAA200906360A patent/UA97502C2/ru unknown
- 2007-12-13 US US12/002,082 patent/US7750051B2/en not_active Expired - Fee Related
- 2007-12-13 DK DK07862906.0T patent/DK2101569T3/da active
- 2007-12-13 CN CN2007800458662A patent/CN101557706B/zh not_active Expired - Fee Related
2009
- 2009-05-27 IL IL198985A patent/IL198985A0/en unknown
- 2009-07-08 NO NO20092611A patent/NO20092611L/no not_active Application Discontinuation
2010
- 2010-01-08 US US12/655,827 patent/US8614252B2/en not_active Expired - Fee Related
- 2010-01-08 US US12/655,828 patent/US20100144887A1/en not_active Abandoned
2012
- 2012-01-11 CY CY20121100022T patent/CY1112511T1/el unknown
2014
- 2014-08-14 US US14/459,877 patent/US20150038744A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL198985A0 (en)	2010-02-17
EP2101569A1 (en)	2009-09-23
US20100145101A1 (en)	2010-06-10
US20150038744A1 (en)	2015-02-05
WO2008076348A1 (en)	2008-06-26
MX2009006251A (es)	2009-10-12
US7750051B2 (en)	2010-07-06
HK1129276A1 (en)	2009-11-27
CN101557706B (zh)	2013-08-07
US20100144887A1 (en)	2010-06-10
EA200970581A1 (ru)	2009-12-30
JP5623081B2 (ja)	2014-11-12
AU2007334428A1 (en)	2008-06-26
NZ577460A (en)	2012-01-12
KR20090089894A (ko)	2009-08-24
EP2101569A4 (en)	2009-12-02
ATE528989T1 (de)	2011-11-15
EA016820B1 (ru)	2012-07-30
RS52183B (sr)	2012-10-31
WO2008076348A8 (en)	2008-08-21
CA2672414A1 (en)	2008-06-26
JP2010513282A (ja)	2010-04-30
EP2101569B1 (en)	2011-10-19
US8614252B2 (en)	2013-12-24
UA97502C2 (ru)	2012-02-27
KR101459744B1 (ko)	2014-11-20
CN101557706A (zh)	2009-10-14
SI2101569T1 (sl)	2012-02-29
ZA200903903B (en)	2010-08-25
AU2007334428B2 (en)	2014-05-29
NO20092611L (no)	2009-09-11
CY1112511T1 (el)	2015-12-09
ES2375761T3 (es)	2012-03-06
US20080161408A1 (en)	2008-07-03
PL2101569T3 (pl)	2012-03-30
HRP20110980T1 (hr)	2012-02-29
PT2101569E (pt)	2012-01-13

Publication	Publication Date	Title
ATE528989T1 (de)	2011-11-15	Kristalline feste rasagilin-base
TW200732349A (en)	2007-09-01	Anti-OX40L antibodies and methods using same
JO2778B1 (en)	2014-03-15	Certain Compounds, Compositions and Methods
MX2009006252A (es)	2009-10-13	Sal de tanato de rasagilina.
MX2010002974A (es)	2010-07-29	Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
ATE526318T1 (de)	2011-10-15	Farnesoid-x-rezeptor-agonisten
PH12015500550A1 (en)	2016-06-13	Anti-notch1 nrr antibodies and methods using same
HN2006011218A (es)	2008-09-17	Composiciones de tigeciclina y métodos de preparación
BR112012014082A2 (pt)	2017-05-23	composições e métodos que compreendem variantes de protease
DK3219705T3 (da)	2020-04-14	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
PH12012501346A1 (en)	2012-12-17	Heteroaryl compounds and uses thereof
MY173526A (en)	2020-01-31	Novel anti-?5?1 antibodies and uses thereof
NO20080991L (no)	2008-05-15	Bazedoksifen acetat formuleringer
ATE530170T1 (de)	2011-11-15	Paliperidonformulierung mit verzögerter freisetzung
WO2008057291A3 (en)	2008-07-03	Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
WO2008088779A3 (en)	2009-05-14	Solid state forms of 5-azacytidine and processes for preparation thereof
BRPI0508064A (pt)	2007-07-17	flavivìrus, composição de vacina e molécula de ácido nucléico
UY31103A1 (es)	2009-01-05	Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones
TW200738649A (en)	2007-10-16	Calcilytic compounds
EA200600590A1 (ru)	2006-08-25	Фармацевтические композиции модафинила с модифицированным высвобождением
ATE552832T1 (de)	2012-04-15	Antidepressivum-propharmaka
WO2008015584A3 (en)	2008-06-12	Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
ATE539082T1 (de)	2012-01-15	Oxazinylisoflavonoidverbindungen, medikamente und anwendungen
WO2006091836A8 (en)	2007-04-12	Formulations of ladostigil tartrate
TW200638932A (en)	2006-11-16	CCI-779 polymorph and use thereof